AI Financial Corp
AIFCNasdaq
$0.55
↑ +1.6%Jul 17 close · end-of-day
Price
1Y↓ -92.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$70.3M
Enterprise Value
$54.9M
P/E
—
P/S
2.8
P/B
0.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$24.7M
Net Income (TTM)
-$613.6M
Free Cash Flow (TTM)
—
Gross Margin
47.9%
Operating Margin
-95.7%
Net Margin
-2483.9%
ROE
-69.0%
ROIC
-2.1%
Debt / Equity
0.0
Net Cash
$15.4M
Return 1Y
-92.9%
Company profile
JanOne Inc. focuses on identifying, acquiring, licensing, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease.
- CEO
- Antonios Isaac
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 170
- Headquarters
- Nevada
- Website
- janone.com
Earnings
AIFC Q1 2026 Earnings
Period ends 2026-03-28
MetricActualYoY
Revenue$4.7M↓ -2.8%
Diluted EPS-$2.14↑ +1326.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $33.9M | $40.0M | $0.00 | $0.00 | $12.5M | $24.8M |
| Gross profit | $8.8M | $8.9M | $0.00 | $0.00 | $5.6M | $10.2M |
| Operating income | -$9.0M | -$16.8M | -$3.1M | -$19.8M | -$6.9M | -$22.9M |
| Net income | -$8.5M | -$16.9M | $11.0M | -$7.8M | -$7.6M | -$344.5M |
| Diluted EPS | -$4.59 | -$6.35 | $3.49 | -$1.95 | -$0.68 | -$5.91 |
| Operating cash flow | -$617,000.00 | -$5.3M | -$3.1M | $1.5M | $1.8M | -$7.2M |
| Free cash flow | -$1.1M | -$7.0M | -$3.9M | — | — | -$7.2M |
| Gross margin | 26.1% | 22.2% | — | — | 45.1% | 41.0% |
| Operating margin | -26.6% | -41.9% | — | — | -55.2% | -92.0% |
| Net margin | -25.1% | -42.2% | — | — | -60.4% | -1386.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $4.9M | $5.4M | $4.8M | $6.4M | $7.6M | $6.0M | $4.7M |
| Gross profit | $1.1M | $2.4M | $2.2M | $1.9M | $2.8M | $2.6M | $2.9M | $3.6M |
| Operating income | -$2.4M | -$732,000.00 | -$2.0M | -$1.9M | -$2.1M | -$16.5M | -$2.3M | -$2.7M |
| Net income | $589,000.00 | -$822,000.00 | -$5.2M | -$2.4M | -$9.1M | $49.0M | -$382.0M | -$271.5M |
| Diluted EPS | $0.07 | -$0.06 | -$0.35 | -$0.15 | -$0.49 | $0.29 | -$5.56 | -$2.14 |
| Operating cash flow | $80,000.00 | $4.2M | -$2.0M | -$1.4M | -$5.3M | -$8.7M | $8.3M | -$12.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 50.6% | 47.8% | 40.4% | 39.7% | 43.5% | 34.6% | 47.4% | 75.8% |
| Operating margin | -112.2% | -14.8% | -36.0% | -40.1% | -32.8% | -218.3% | -37.6% | -58.2% |
| Net margin | 27.2% | -16.6% | -95.7% | -49.3% | -142.9% | 646.4% | -6326.0% | -5761.7% |
Company news
Apr 25, 2026
Apr 24, 2026
Feb 5, 2026
Jan 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-14 | DANZIGER DAVID C. | Buy | 10,000 | $7.30 | $73,000.00 | filing |
| 2025-07-02 | DANZIGER DAVID C. | Award | 10,000 | $7.88 | $78,800.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.